Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

BioTelemetry (BEAT) Stock Forecast & Price Target

BioTelemetry logo
Get the Latest News and Ratings for BEAT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioTelemetry and its competitors.

Sign Up

BEAT Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.00$8.00$8.00$6.78
Forecasted Upside222.58% Upside266.97% Upside240.43% Upside398.16% Upside
Consensus Rating
Buy
Buy
Buy
Buy

BEAT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BEAT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioTelemetry Stock vs. The Competition

TypeBioTelemetryMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside222.58% Upside26,931.56% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent BEAT News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2024Benchmark
2 of 5 stars
W. Sutherland
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$8.00 ➝ $8.00+252.42%
5/19/2023Alliance Global Partners
1 of 5 stars
 Lower Target$10.00 ➝ $5.55+151.13%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:48 AM ET.


BEAT Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for BioTelemetry is $8.00, with a high forecast of $8.00 and a low forecast of $8.00.

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BEAT shares.

According to analysts, BioTelemetry's stock has a predicted upside of 222.58% based on their 12-month stock forecasts.

BioTelemetry has been rated by research analysts at Benchmark in the past 90 days.

Analysts like BioTelemetry more than other "medical" companies. The consensus rating for BioTelemetry is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BEAT compares to other companies.


This page (NASDAQ:BEAT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners